View in EDS

Can preclinical drug development help to predict adverse events in clinical trials?

Saved in:
Bibliographic Details
Title: Can preclinical drug development help to predict adverse events in clinical trials?
Authors: Chi LH; Translational Breast Cancer Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Burrows AD; Translational Breast Cancer Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Anderson RL; Translational Breast Cancer Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. Electronic address: robin.anderson@onjcri.org.au.
Source: Drug discovery today [Drug Discov Today] 2022 Jan; Vol. 27 (1), pp. 257-268. Date of Electronic Publication: 2021 Aug 29.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9604391 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-5832 (Electronic) Linking ISSN: 13596446 NLM ISO Abbreviation: Drug Discov Today Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34469805
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Can preclinical drug development help to predict adverse events in clinical trials?
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chi+LH%22">Chi LH</searchLink>; Translational Breast Cancer Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Burrows+AD%22">Burrows AD</searchLink>; Translational Breast Cancer Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Anderson+RL%22">Anderson RL</searchLink>; Translational Breast Cancer Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. Electronic address: robin.anderson@onjcri.org.au.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229604391%22">Drug discovery today</searchLink> [Drug Discov Today] 2022 Jan; Vol. 27 (1), pp. 257-268. <i>Date of Electronic Publication: </i>2021 Aug 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ltd%22">Elsevier Science Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9604391 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1878-5832 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213596446%22">13596446 </searchLink><i>NLM ISO Abbreviation: </i>Drug Discov Today <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34469805
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.drudis.2021.08.010
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 257
    Titles:
      – TitleFull: Can preclinical drug development help to predict adverse events in clinical trials?
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chi LH
      – PersonEntity:
          Name:
            NameFull: Burrows AD
      – PersonEntity:
          Name:
            NameFull: Anderson RL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2022 Jan
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1878-5832
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Drug discovery today
              Type: main
ResultId 1